Petros Pharmaceuticals (PTPI) Competitors $0.03 0.00 (-8.01%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. CANF, SONN, JAGX, PCSA, ARTL, ELAB, SPRC, PPBT, ONVO, and NBYShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Can-Fite BioPharma (CANF), Sonnet BioTherapeutics (SONN), Jaguar Health (JAGX), Processa Pharmaceuticals (PCSA), Artelo Biosciences (ARTL), Elevai Labs (ELAB), SciSparc (SPRC), Purple Biotech (PPBT), Organovo (ONVO), and NovaBay Pharmaceuticals (NBY). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors Can-Fite BioPharma Sonnet BioTherapeutics Jaguar Health Processa Pharmaceuticals Artelo Biosciences Elevai Labs SciSparc Purple Biotech Organovo NovaBay Pharmaceuticals Can-Fite BioPharma (NYSE:CANF) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability. Do insiders and institutionals believe in CANF or PTPI? 21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to CANF or PTPI? In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 1 articles in the media. Can-Fite BioPharma's average media sentiment score of 1.00 beat Petros Pharmaceuticals' score of -1.00 indicating that Can-Fite BioPharma is being referred to more favorably in the media. Company Overall Sentiment Can-Fite BioPharma Positive Petros Pharmaceuticals Negative Do analysts recommend CANF or PTPI? Can-Fite BioPharma currently has a consensus target price of $14.00, suggesting a potential upside of 1,208.41%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Petros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in CANF or PTPI? Can-Fite BioPharma received 9 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 12.20% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformCan-Fite BioPharmaOutperform Votes1012.20%Underperform Votes7287.80% Petros PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Which has better earnings & valuation, CANF or PTPI? Can-Fite BioPharma has higher earnings, but lower revenue than Petros Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$674K5.62-$7.63M-$1.79-0.60Petros Pharmaceuticals$5.11M0.19-$8.16M-$119.000.00 Which has more risk and volatility, CANF or PTPI? Can-Fite BioPharma has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Is CANF or PTPI more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A Petros Pharmaceuticals N/A -78.22%-23.50% SummaryCan-Fite BioPharma beats Petros Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$966K$6.87B$5.58B$8.49BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.018.5427.1819.64Price / Sales0.19261.73408.37152.20Price / CashN/A65.8538.3234.64Price / Book0.016.536.974.60Net Income-$8.16M$143.48M$3.23B$248.06M7 Day PerformanceN/A0.27%-0.84%-0.97%1 Month PerformanceN/A11.00%7.86%3.56%1 Year PerformanceN/A2.49%31.51%12.68% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.3949 of 5 stars$0.03-8.0%N/A-99.7%$966K$5.11M-0.0120Short Interest ↑CANFCan-Fite BioPharma3.1723 of 5 stars$1.11+1.4%$14.00+1,161.3%-65.6%$3.93M$674K-0.628Short Interest ↓Gap UpSONNSonnet BioTherapeutics2.8225 of 5 stars$1.22-2.2%$20.00+1,535.3%-34.1%$3.87M$1M0.0010News CoverageShort Interest ↓JAGXJaguar Health2.5662 of 5 stars$3.80-6.4%$60.00+1,478.9%-95.8%$3.87M$11.55M0.0050High Trading VolumePCSAProcessa Pharmaceuticals3.1012 of 5 stars$0.32+8.0%$6.00+1,747.9%-78.5%$3.86MN/A-0.1020News CoveragePositive NewsGap DownARTLArtelo Biosciences2.1125 of 5 stars$1.11-0.9%$5.50+395.5%-11.2%$3.64MN/A-0.395Analyst DowngradeStock SplitShort Interest ↓Gap DownELABElevai Labs1.0889 of 5 stars$2.64+21.7%N/A-99.8%$3.63M$2.45M-0.0418Gap UpHigh Trading VolumeSPRCSciSparc0.9935 of 5 stars$0.33+4.2%N/A-64.2%$3.52M$1.31M0.004Short Interest ↓Gap DownPPBTPurple Biotech2.6685 of 5 stars$2.61-0.4%$33.00+1,164.4%N/A$3.47MN/A-0.3020ONVOOrganovoN/AN/AN/AN/A$3.47M$122K-2.4020Gap UpNBYNovaBay PharmaceuticalsN/A$0.59+2.5%$0.85+43.0%-77.7%$3.46M$9.78M-0.0130 Related Companies and Tools Related Companies Can-Fite BioPharma Competitors Sonnet BioTherapeutics Competitors Jaguar Health Competitors Processa Pharmaceuticals Competitors Artelo Biosciences Competitors Elevai Labs Competitors SciSparc Competitors Purple Biotech Competitors Organovo Competitors NovaBay Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
